Skip to content

The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05579353
Enrollment
200
Registered
2022-10-13
Start date
2023-01-01
Completion date
2026-12-31
Last updated
2022-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.

Interventions

OTHERnothing

nothing

Sponsors

Jingbo Chen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1.18-80 years old. 2.18.5 \< BMI \< 27.9. 3\. The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.

Exclusion criteria

1. Those who refuse to collect samples. 2. Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases. 3. Patients who has a history of neoadjuvant radiotherapy or chemotherapy. 4. Combining with distant multiple metastases of tumor

Design outcomes

Primary

MeasureTime frameDescription
expressional quantityThrough study completion, an average of 2 yearExpression of CRTC2 in patient samples

Countries

China

Contacts

Primary ContactJingbo Chen, doctor
qychenjingbo@163.com15053186972

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026